MedPath

Effect of Unani formulation in Tinea Corporis

Phase 2
Not yet recruiting
Conditions
Other specified local infections of the skin and subcutaneous tissue,
Registration Number
CTRI/2022/08/044906
Lead Sponsor
Government unani medical college and hospital Bengaluru Karnataka
Brief Summary

Clinically diagnosed casesof tinea corporis fulfilling the inclusion criteria after obtaining writtenconsent will be enrolled in the intervention of Nuqoo-e-Mundi(orally) 7 gmswith 30 ml of water and local application of Roghan-e- Neem (twice a day) for aduration of 28 days with follow up assessment on every 7th day (7th14th 21st28th35th day). The preand post treatment objective findings(effects) will be assessed.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Patients age between 18-60 years of all gender Mycological(KOH) confirmed cases of tinea corporis (KOH +ve cases) Patients with 2 years of chronicity of tinea corporis Patients who are willing to sign the consent form for the trial.

Exclusion Criteria

Age group less than 18 years or more than 60 years Patients with DM HTN renal and hepatic impairement hypersensitivity to drug Patients with severe skin infections Pregnant and lactating mothers Cases other than tinea corporis Patient on corticosteroid treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
KOH examination of skin scrap should be negative28 days
Secondary Outcome Measures
NameTimeMethod
Reduction in subjective parameters will be according to arbitrary grading scale or physicians global assesment score0th 7th 14th 21st 28th 35th day

Trial Locations

Locations (1)

Government Unani Medical College and Hospital

🇮🇳

Bangalore, KARNATAKA, India

Government Unani Medical College and Hospital
🇮🇳Bangalore, KARNATAKA, India
Dr Sayema khan
Principal investigator
7289805073
sayemakhan91@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.